Hatem E. Sabaawy
YOU?
Author Swipe
View article: Evolutionary conserved reciprocal senescence and tumor suppressor signals limit lifetime cancer
Evolutionary conserved reciprocal senescence and tumor suppressor signals limit lifetime cancer Open
Cellular senescence features a durable exit from the cell cycle triggered by stress or carcinogens. The INK4 locus is inactivated in various cancers, yet in senescence, p16 Ink4a is activated. Whether senescence is tumor-suppressing or -pr…
View article: Editorial: Patient-derived tumor models for drug development
Editorial: Patient-derived tumor models for drug development Open
EDITORIAL article Front. Oncol., 07 July 2023Sec. Cancer Molecular Targets and Therapeutics Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1243534
View article: Data from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Data from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition Open
Glioblastoma (GBM) is the most frequent and lethal brain cancer. The lack of early detection methods, the presence of rapidly growing tumor cells, and the high levels of recurrence due to chemo- and radioresistance make this cancer an extr…
View article: Supplementary Tables 1-7 from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Supplementary Tables 1-7 from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition Open
Supplementary Tables 1-7. Supplementary Table 1. Antibodies and conditions used for IF, IHC, flow cytometry and western blotting; Supplementary Table 2. Multiple comparisons in treatment effects adjusted for type of cell lines of U87 or U3…
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Data from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Data from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition Open
Glioblastoma (GBM) is the most frequent and lethal brain cancer. The lack of early detection methods, the presence of rapidly growing tumor cells, and the high levels of recurrence due to chemo- and radioresistance make this cancer an extr…
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
View article: Data from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Data from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Only a small percentage (<1%) of patients with late-stage lung squamous cell carcinoma (LUSC) are eligible for targeted therapy. Because PI3K/AKT/mTOR signaling, particularly Phosphatidylinositol 3-kinase CA (PIK3CA), is dysregulated in tw…
View article: Data from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Data from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Only a small percentage (<1%) of patients with late-stage lung squamous cell carcinoma (LUSC) are eligible for targeted therapy. Because PI3K/AKT/mTOR signaling, particularly Phosphatidylinositol 3-kinase CA (PIK3CA), is dysregulated in tw…
View article: Supplementary Tables 1-7 from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
Supplementary Tables 1-7 from Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition Open
Supplementary Tables 1-7. Supplementary Table 1. Antibodies and conditions used for IF, IHC, flow cytometry and western blotting; Supplementary Table 2. Multiple comparisons in treatment effects adjusted for type of cell lines of U87 or U3…
View article: Data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Open
Purpose: Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1 reg…
View article: Supplementary data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Supplementary data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Open
Supplementary data Figure S1. Functional role(s) of BMI-1 in PCa. Figure S2. BMI-1 expression in subpopulations of DU145 cells. Figure S3. Pharmacological inhibition of BMI-1. Figure S4. Molecular and cellular effects of pharmacological ta…
View article: Supplementary data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Supplementary data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Open
Supplementary data Figure S1. Functional role(s) of BMI-1 in PCa. Figure S2. BMI-1 expression in subpopulations of DU145 cells. Figure S3. Pharmacological inhibition of BMI-1. Figure S4. Molecular and cellular effects of pharmacological ta…
View article: Data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Data from BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Open
Purpose: Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1 reg…
View article: RNAseq data on control (TC11EV1-4) and Sox9 overexpressing (TC11S1-4) murine lung adenocarcinoma syngeneic allograft samples
RNAseq data on control (TC11EV1-4) and Sox9 overexpressing (TC11S1-4) murine lung adenocarcinoma syngeneic allograft samples Open
RNAseq data on the empty vector control and Sox9 overexpressing samples
View article: <i>shox2</i> is required for vestibular statoacoustic neuron development
<i>shox2</i> is required for vestibular statoacoustic neuron development Open
Homeobox genes act at the top of genetic hierarchies to regulate cell specification and differentiation during embryonic development. We identified the short stature homeobox domain 2 (shox2) transcription factor that is required for vesti…
View article: Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma Open
Only a small percentage (<1%) of patients with late-stage lung squamous cell carcinoma (LUSC) are eligible for targeted therapy. Because PI3K/AKT/mTOR signaling, particularly Phosphatidylinositol 3-kinase CA (PIK3CA), is dysregulated in…
View article: Optimized 3D Culture of Hepatic Cells for Liver Organoid Metabolic Assays
Optimized 3D Culture of Hepatic Cells for Liver Organoid Metabolic Assays Open
The liver is among the principal organs for glucose homeostasis and metabolism. Studies of liver metabolism are limited by the inability to expand primary hepatocytes in vitro while maintaining their metabolic functions. Human hepatic thre…
View article: JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance
JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance Open
Inflammation is at the forefront of carcinogenesis, tumor progression and resistance to therapy. The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling axis is a central pathway that mediates the cellular …
View article: Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening
Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening Open
Robust patient-derived platforms that recapitulate the cellular and molecular fingerprints of glioblastoma are crucial for developing effective therapies. Here, we describe a chemically defined protocol for 3D culture and propagation of gl…